Trials of gene therapy for pancreatic carcinoma

Current Gastroenterology Reports

Volumn 7, Issue 3, 2005, Pages 165-169

  Halloran, Christopher M ^a   Ghaneh, Paula ^a   Costello, Eithne ^a   Neoptolemos, John P ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADENOVIRUS VECTOR; ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; COMPLEMENTARY RNA; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B6; CYTOSINE DEAMINASE; CYTOTOXIC AGENT; FLUCYTOSINE; FLUOROURACIL; FOLINIC ACID; GANCICLOVIR; GEMCITABINE; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; IFOSFAMIDE; INTERLEUKIN 12; K RAS PROTEIN; MATRIX METALLOPROTEINASE; MUCIN 1; MUCIN 4; ONCOLYTIC VIRUS; PRODRUG; PROTEIN P16INK4A; PROTEIN P53; SMAD4 PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; THYMIDINE KINASE; TNFERADE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DRUG MECHANISM; DRUG METABOLISM; ENZYME THERAPY; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; GENOMICS; HUMAN; MELANOMA; NONHUMAN; NOTE; ONCOGENE K RAS; OVARY CANCER; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; SURVIVAL RATE; VIRAL GENE THERAPY;

EID: 21444446011     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-005-0028-7     Document Type: Note

References (69)

1. Neoptolemos JP, Russell RC, Bramhall S, Theis B: Low mortality following resection for pancreatic and periampulliary tumours in 1026 patients: UK survey of specialist pancreatic units. UK pancreatic cancer group. Br J Surg 1997, 84:1370-1376.
2. Pasquali C, Sperti C, Filipponi C, Pedrazzoli S: Epidemiology of pancreatic cancer in Northeastern Italy: incidence, resectability rate, hospital stay, costs and survival (1990-1992). Dig Liver Dis 2002, 34:723-731.
3. Sener SF, Fremgen A, Menck HR, Winchester DP: Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the national cancer database. J Am Coll Surg 1999, 189:1-7.
4. Andren-Sandberg A, Neoptolemos JP: Resection for pancreatic cancer in the new millennium. Pancreatology 2002, 2:431-439.
5. Edge SB, Schmieg RE Jr, Rosenlof LK, Wilhelm MC: Pancreas cancer resectional outcome in American University Centers in 1988-1990. Cancer 1993, 71:3502-3508.
6. Conlon KC, Klimstra DS, Brennan MF: Long term survival after curative resection for pancreatic ductal adenocarcinoma: Clinical-pathological analysis of 5-year survivors. Ann Surg 1996, 223:613-622.
7. Allema JH, Reinders ME, van Gulik TM, et al.: Prognostic factors for survival after pancreatioduodenectomy for patients with carcinoma of the pancreatic head region. Cancer 1995, 75:2069-2076.
8. Nitecki SS, Sarr MG, Colby TV, van Heerden JA: Long-term survival after resection for ductal adencarcinoma of the pancreas. Is it really improving? Ann Surg, 1995, 221:59-66.
9. Mosca F, Giulianotti PC, Balestracci T, et al.: Long-term survival in pancreatic cancer: pylorus-preserving versus Whipple pancreaoduodenectomy. Surgery 1997, 122:553-566.
10. Yeo CJ, Cameron JL, Sohn TA, et al.: Six hundred fifty consecutive pancreaticoduodenectomies in the 1990's: pathology, complications and outcomes. Ann Surg 1997, 226:248-260.
11. Yeo CJ, Cameron JL, Sohn TA, et al.: Pancretoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampulliary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. Ann Surg 1999, 229:613-622.
12. Allison DC, Piantadosi S, Hruban RH, et al.: DNA content and other factors associated with ten year survival after resection of pancreatic carcinoma. J Surg Oncol 1998, 67:151-159.
13. Finlayson EV, Birkmeyer JD: Effects of hospital volume on life expectancy after selected cancer operations in older adults: a decisional analysis. J Am Coll Surg 2003, 196:410-417.
14. Northern and Yorkshire Cancer Registry and Information Service: Cancer treatment policies and their effect on survival. Pancreas 2000, 4.3:19.
15. Halloran CM, Ghaneh P, Bosonnet L, et al.: Complications of pancreatic cancer resection. Dig Surg 2002, 19:138-146.
16. Hertel LW, Boder GB, Kroin JS, et al.: Evaluation of the antitumour activity of gemcitabine (2′,2′-diflluoro-2′-deoxycytidine). Cancer Res 1990, 50:4417-4422.
17. Huang P, Chubb S, Hertel LW, et al.: Action of 2′,2′-difluorodeoxycitadine on DNA synthesis. Cancer Res 1991, 51:6110-6117.
18. Haycox A, Lombard M, Neoptolemos J, Walley T: Review article: current treatment and optimal patient management in pancreatic cancer. Aliment Pharmacol Ther 1998, 12:949-964.
19. Sotos GA, Grogan L, Allegra CJ: Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treat Rev 1994, 20:11-49.
20. Burris HA III, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomised trial. J Clin Oncol 1997, 15:2403-2413.
21. Klinkenbijl JH, Jeekel J, Sahmoud T, et al.: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampulliary region. A phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 1999, 230:776-784.
22. Neoptolemos JP, Dunn JA, Stocken DD, et al.: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001, 358:1576-1585.
23. Bramhall SR, Allum WH, Jones AG, et al.: Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 1995, 82:111-115.
24. Halloran CM, Ghaneh P, Neoptolemos JP, Costello E: Gene therapy for pancreatic cancer: current and prospective strategies. Surg Oncol 2000, 9:181-191.
25. Moskaluk CA, Hruban RH, Kern SE: p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 1997, 57:2140-2143.
26. Barton CM, McKie AB, Hogg A, et al.: Abnormalities of the RB1 and DCC tumor suppressor genes: uncommon in human pancreatic adenocarcinoma. Mol Carcinog 1995, 13:61-69.
27. Rozenblum E, Schutte M, Goggins M, et al.: Tumour suppresser pathways in pancreatic cancer. Cancer Res 1997, 57:1731-1734.
28. Katoh H, Kuzumaki N, Schichiwohe T, et al.: Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y. J Surg Res, 1996. 66:25-130.
29. Takeuchi M, Shichinohe T, Senmaru N, et al.: The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice. Gene Ther 2000, 7:518-526.
30. Gjertsen MK, Bjorheim J, Saeterdal I, et al.: Cytotoxic CD4+ and CD8+ T lymphocytes generated by mutant p21-ras (12 val) peptide vaccination of a patient recognise 12 val dependant nested epitopes present with in the vaccine peptide and kill autologous tumour cells carrying this mutant. Int J Cancer 1997, 72:784-790.
31. Gjertsen MK, Saeterdal I, Thorsby E, Gaudernack G: Characterisation of immune response in pancreatic cancer patients after mutant p21-ras peptide vaccination. Br J Cancer 1996, 74:1828-1833.
32. Aoki K, Yoshida T, Sugimura T, Terada M: Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumour dissemination in the murine peritoneal cavity. Cancer Res 1995, 55:3810-3816.
33. Aoki K, Yoshida T, Matsumoto N, et al.: Suppression of Ki-ras p21-ras levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras muations but not those with out Ki-ras mutations. Mol Carcinog 1997, 20:251-258.
34. Hatanaka K, Suzuki K, Miura Y, et al.: Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer. J Gene Med 2004, 6:1139-1148.
35. Hollstein M, Rice K, Greenblatt MS, et al.: Database of p53 gene somatic mutations in human tumours and cell lines. Nucleic Acids Res 1994, 22:3551-3555.
36. Bossi G, Mazzaro G, Porrello A, et al.: Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy. Oncogene 2004, 23:418-425.
37. Ghaneh P, Greenhalf W, Humphreys M, et al.: Adenovirus-mediated transfer of p53 and p16(INK4a) results in pancreatic cancer regression in vitro and in vivo. Gene Ther 2001, 8:199-208.
38. Bouvet M, Bold RJ, Lee J, et al.: Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Ann Surg Oncol 1998, 5:681-688.
39. Kawesha A, Ghaneh P, Andren-Sandberg A, et al.: K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), Cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinioma. Int J Cancer 2000, 89:469-474.
40. Caldas C, Hahn SA, da Costa LT, et al.: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994, 8:27-32.
41. Schutte M, Hruban RH, Geradts J, et al.: Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997, 57:3126-3130.
42. Kobayashi S, Shirasawa H, Sashiyama H, et al.: P16INK4a expression adenovirus vector to suppress pancreas cancer cell proliferation. Clin Cancer Res 1999, 5:4182-4185.
43. Cascallo M, Mercade E, Capella G, et al.: Genetic background determines the response to adenovirus-mediated wild-type p53 expression in pancreatic tumor cells. Cancer Gene Ther 1999, 6:428-436.
44. Schreiber M, Muller WJ, Singh G, Graham FL: Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21(WAF1/CIP1) and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumourigenicity. Oncogene 1999, 18:1663-1676.
45. Halloran CM, Ghaneh P, Shore S, et al.: 5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells. J Gene Med 2004, 5:514-525.
46. Sangro B, Mazzolini G, Ruiz J, et al.: Phase I trial of intertumoural injection of an adenovirus encoding interlukin-12 for advanced digestive tumours. J Clin Oncol 2004, 8:1389-1397.
47. Clinicaltrials.gov http://www.nci.nih.gov./ct/show/NCT00051467
48. Huber BE, Austin EA, Richards CA, et al.: Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci U S A 1994, 91:8302-8306.
49. DiMaio JM, Clary BM, Via DF, et al.: Directed enzyme pro drug therapy for pancreatic cancer in vivo. Surgery 1994, 116:205-113.
50. Di Magno EP, Reber HA, Tempero MA: AGA technical review on the epidemiology, diagnosis and treatment of pancreatic ductal adenocarcinoma. Gastoenterology 1998, 117:1464-1484.
51. Ohashi M, Kanai F, Tanaka T, et al.: In vivo adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing pancreatic cancer. Jpn J Cancer Res 1998, 89:457-462.
52. Kleeff J, Fukahi K, Lopez ME, et al.: Targeting of suicide gene delivery in pancreatic cancer cells via FGF receptors. Cancer Gene Ther 2002, 9:522-532.
53. Huber BE, Austin EA, Good SS, et al.: In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 1993, 53:4619-4626.
54. Evoy D, Hirschowitz EA, Naama HA, et al.: In vivo adenoviral mediated gene transfer in the treatment of pancreatic cancer. J Surg Res 1997, 69:226-231.
55. Kan O, Kingsman S, Naylor S: Cytochrome P450-based cancer gene therapy: current status. Expert Opin Biol Ther 2002, 2:857-868.
56. Oxford Biomedica. http://www.oxfordbiomedica.co.uk/metxia.htm
57. Cancer Research UK. http://www.cancerhelp.org.uk/trials/trials/ trial.asp?freetextsearch=&searchtype=select&trials =4994&tri-alno=4449&soage=1&objective=0&cancer= 93&stage=0&phase=0&treatment=0&location=0
58. Division of Surgery and Oncology, University of Liverpool. http://www.liv.ac.uk/surgery/Metxia.html
59. Lohr M, Hoffmeyer A, Kroger J, et al.: Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet 2001, 357:1591-1592.
60. Lohr M, Hummel F, Faulmann G, et al.: Microencapsulated, CYP2B1-transfected cells activating ifosfamide at the site of the tumour: the magic bullets of the 21st century. Cancer Chemother Pharmacol 2002, 49:S21-S24.
61. Ryschich E, Jesnowski R, Ringel J, et al.: Combined therapy of experimental pancreatic cancer with CYP2B1 producing cells: Low dose ifosfamide and local tumour irradiation. Int J Cancer 2005, 113:649-653.
62. Barker DD, Berk AJ: Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 1987, 156:107-121.
63. Bischoff JR, Kirn DH, Williams A, et al.: An adenovirus mutant that replicates selectively in p53-defecient human tumour cells. Science 1996, 274:373-376.
64. Flint J, Shenk T: Viral transactivating proteins. Annu Rev Genet 1997, 3:177-212.
65. Ries S, Korn WM: ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer 2002, 86:5-11.
66. Hecht JR, Bedford R, Abbruzzese JL, et al.: A phase I/II trial of intratumoural endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Can Res 2003, 9:555-561.
67. Mulvihill S, Warren R, Venook A, et al.: Safety and feasibility of injection with an E1B-55kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 2001, 8:308-315.
68. Gordon EM, Chen ZH, Liu L, et al.: Systemic administration of a matrix-targetted retroviral vector is efficacious for cancer gene therapy in mice. Hum Gene Ther 2001, 12:193-204.
69. Gordon EM, Cornelio GH, Lorenzo CC III, et al.: First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer. Int J Oncol 2004, 24:177-185.